{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:04:53Z","timestamp":1789812293222,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001412","name":"CSIR","doi-asserted-by":"publisher","award":["MLP-6010"],"award-info":[{"award-number":["MLP-6010"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"CSIR","doi-asserted-by":"publisher","award":["BSC-203"],"award-info":[{"award-number":["BSC-203"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"DBT-GOI","doi-asserted-by":"publisher","award":["GAP-2176"],"award-info":[{"award-number":["GAP-2176"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"DBT-GOI","doi-asserted-by":"publisher","award":["Ramalingaswami Fellowship-GAP-1160"],"award-info":[{"award-number":["Ramalingaswami Fellowship-GAP-1160"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"CSIR","doi-asserted-by":"publisher","award":["MLP-6010"],"award-info":[{"award-number":["MLP-6010"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"DBT, GOI","doi-asserted-by":"publisher","award":["GAP-1160"],"award-info":[{"award-number":["GAP-1160"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.ijantimicag.2018.09.019","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T03:11:59Z","timestamp":1537931519000},"page":"49-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["In vitro evaluation of dinactin, a potent microbial metabolite against Mycobacterium tuberculosis"],"prefix":"10.1016","volume":"53","author":[{"given":"Aehtesham","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9485-6453","authenticated-orcid":false,"given":"Muzafar Ahmad","family":"Rather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2497-0581","authenticated-orcid":false,"given":"Zubair Shanib","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasif","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubashir","family":"Maqbool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aabid Manzoor","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mushtaq A","family":"Aga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiyatullah","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payare L","family":"Sangwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qazi Parvaiz","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5694-9600","authenticated-orcid":false,"given":"Zahoor","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0001","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ccm.2009.08.017","article-title":"Global burden and epidemiology of tuberculosis","volume":"30","author":"Glaziou","year":"2009","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0002","unstructured":"WHO. Global tuberculosis report 2016. http:\/\/reliefweb.int\/sites\/reliefweb.int\/files\/resources\/gtbr2016 main text.pdf."},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0003","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrmicro749","article-title":"Tuberculosis: a problem with persistence","volume":"1","author":"Stewart","year":"2003","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0004","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1086\/651491","article-title":"Extensively drug-resistant tuberculosis: \u201cthere must be some kind of way out of here\u201d","volume":"50","author":"Cegielski","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0005","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1086\/651500","article-title":"From HIV to tuberculosis and back again: a tale of activism in 2 pandemics","volume":"50","author":"Harrington","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0006","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMra1200894","article-title":"Current concepts","volume":"368","author":"Zumla","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0007","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2165\/11538170-000000000-00000","article-title":"Drugs in development for tuberculosis","volume":"70","author":"Ginsberg","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0008","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1039\/c0np00008f","article-title":"Bioprospecting for antituberculosis leads from microbial metabolites","volume":"27","author":"Ashforth","year":"2010","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0009","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/emmm.201201811","article-title":"Back to the future: a new \u2018old\u2019 lead for tuberculosis","volume":"4","author":"Wright","year":"2012","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0010","doi-asserted-by":"crossref","unstructured":"Lechartier B, Rybniker J, Zumla A, Cole ST. Tuberculosis drug discovery in the post\u2010post\u2010genomic era. EMBO Mol Med 2014:e201201772.","DOI":"10.1002\/emmm.201201772"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0011","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nchembio841","article-title":"Developing a new resource for drug discovery: marine actinomycete bacteria","volume":"2","author":"Fenical","year":"2006","journal-title":"Nature Chem Biol"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0012","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s11274-009-0113-4","article-title":"Screening of marine actinomycetes isolated from the Bay of Bengal, India for antimicrobial activity and industrial enzymes","volume":"25","author":"Ramesh","year":"2009","journal-title":"World J Microbiol Biotechnol"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0013","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/lam.12773","article-title":"Antituberculotic activity of actinobacteria isolated from the rare habitats","volume":"65","author":"Hussain","year":"2017","journal-title":"Lett Appl Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0014","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.micres.2017.12.004","article-title":"Streptomyces puniceus strain AS13. Production, characterization and evaluation of bioactive metabolites: a new face of dinactin as an antitumor antibiotic","volume":"207","author":"Hussain","year":"2018","journal-title":"Microbiol Res"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0015","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/jam.13410","article-title":"Discovery of anti\u2010microbial and anti\u2010tubercular molecules from Fusarium solani: an endophyte of Glycyrrhiza glabra","volume":"122","author":"Shah","year":"2017","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0016","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00849-10","article-title":"PA-824 exhibits time-dependent activity in a murine model of tuberculosis","volume":"55","author":"Ahmad","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0017","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/AAC.39.2.440","article-title":"In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli","volume":"39","author":"Luna-Herrera","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0018","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1093\/jac\/dkq374","article-title":"Time\u2013kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis","volume":"65","author":"de Steenwinkel","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0019","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.tube.2012.07.003","article-title":"Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis","volume":"92","author":"Franzblau","year":"2012","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0020","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jmii.2015.08.025","article-title":"Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin\/clavulanate combination","volume":"49","author":"Pagliotto","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0021","doi-asserted-by":"crossref","first-page":"13985","DOI":"10.1038\/srep13985","article-title":"In vitro and in vivo evaluation of synergism between anti-tubercular spectinamides and non-classical tuberculosis antibiotics","volume":"5","author":"Bruhn","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0023","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd2201","article-title":"Drugs for bad bugs: confronting the challenges of antibacterial discovery","volume":"6","author":"Payne","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0024","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nature09657","article-title":"The challenge of new drug discovery for tuberculosis","volume":"469","author":"Koul","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0272-5231(21)00637-7","article-title":"Drug-resistant tuberculosis","volume":"10","author":"Iseman","year":"1989","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1164\/ajrccm\/137.3.711","article-title":"Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex","volume":"137","author":"Heifets","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0027","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1128\/AAC.00474-11","article-title":"Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen","volume":"55","author":"Ramon-Garcia","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0028","doi-asserted-by":"crossref","first-page":"34293","DOI":"10.1038\/srep34293","article-title":"Repurposing clinically approved cephalosporins for tuberculosis therapy","volume":"6","author":"Ramon-Garcia","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/80bc1e50-d623-464f-817f-a5e776b75717","article-title":"Optimal drug synergy in antimicrobial treatments","volume":"6","author":"Torella","year":"2010","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0030","series-title":"Developing antimicrobial drugs-general considerations for clinical trials","year":"1998"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0031","series-title":"Points to consider on pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products","year":"2000"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0032","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/AAC.01533-06","article-title":"Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0033","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Zhang","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0034","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1086\/605605","article-title":"Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig","volume":"200","author":"Ahmad","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0035","series-title":"Drug susceptibility in the chemotherapy of mycobacterial infections","author":"Heifets","year":"1991"},{"key":"10.1016\/j.ijantimicag.2018.09.019_bib0036","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1099\/jmm.0.014837-0","article-title":"In vitro synergistic interactions of oleanolic acid in combination with isoniazid, rifampicin or ethambutol against Mycobacterium tuberculosis","volume":"59","author":"Ge","year":"2010","journal-title":"J Med Microbiol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918302784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918302784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:32:48Z","timestamp":1760376768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918302784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0924857918302784"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.09.019","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro evaluation of dinactin, a potent microbial metabolite against Mycobacterium tuberculosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}